Press

FDA Clearance for AgaMatrix’s High Accuracy Blood Glucose Monitor

Thursday, March 30th, 2006
Original source of this article:
View this article at external source

SALEM, N.H. — AgaMatrix, Inc., a privately held developer and manufacturer of blood glucose monitoring products, announced today that it has received clearance from the United States Food and Drug Administration to sell its high accuracy discrete blood glucose monitoring system (“BGMS”), the Wave 1(TM). The Wave 1(TM) system is being distributed in the US by Liberty Medical(TM), as its Liberty(TM) brand BGMS, and by other distributors internationally.

The Liberty(TM) BGMS incorporates dozens of proprietary technologies, conceptualized and substantiated over several years of research and development, to provide users with industry-leading, world-class accuracy for safer testing.

It is the only system in the world that uses WaveSense(TM), a suite of Dynamic Electrochemistry and digital signal processing technologies that enables superior analytical performance for biosensors.

“With WaveSense(TM) and a team that has experience manufacturing millions of blood glucose meters and test strips, AgaMatrix is in a unique position to deliver an accurate, safe, reliable product to this space,” said John Alberico, the President of AgaMatrix.

Other major makers of products serving the $6 billion BGMS market include Roche (LSE: ROG), Johnson and Johnson (NYSE: JNJ), Bayer (NYSE: BAY), Abbott (NYSE: ABT), and Becton Dickinson (NYSE: BDX).

The Liberty(TM) BGMS features a number of unique functions including a unit of measurement safety lock designed to prevent misinterpretation of results, a double redundant power supply for more reliable data memory, 6 user settable alarms, and both hypoglycemic and hyperglycemic alerts.

About AgaMatrix

AgaMatrix, Inc. (http://agamatrix.com) is a consumer medical device company headquartered in Salem, New Hampshire that develops and manufactures next generation blood glucose monitoring products for the diabetes market. The Company’s proprietary WaveSense(TM) platform, a suite of biosensor and Dynamic Electrochemistry(TM) technologies, enables high accuracy glucose sensing. Current products include a meter and strip system; future products include a cartridge-based system that fully integrates lancets and sensors.

(C) 2001 – 2006 AgaMatrix, Inc. AgaMatrix(TM), WaveSense(TM), KeyNote(TM), Wave 1(TM), Wave 2(TM), Wave 3(TM) and their respective logos are trademarks of AgaMatrix, Inc. Registered trademarks are the property of their owners.